Editor’s Note: This is the latest column from the Society for Acupuncture Research (www.acupunctureresearch.org). Visit the SAR online columnist page for access to previous articles.
Vulvodynia, chronic vulvar pain of unknown origin lasting at least three months, affects approximately 7% of American women and has no consistently effective treatment. Seventy percent of those affected report severe pain scoring above six out of 10, and the condition routinely makes sexual intercourse impossible, devastating intimate relationships and quality of life.
To manage the pain, 60% of women with vulvodynia use alcohol and 43% combine alcohol with analgesics including opioids.
In its most serious form, vulvodynia can lead to physical disability and suicidal ideation. This is the clinical landscape a rigorously designed, double-blind, randomized, controlled trial (RCT) now addresses, providing the most methodologically robust evidence to date that acupuncture offers real and longer-lasting relief for those who respond to it.
Study Overview
This double-blind, placebo-controlled RCT was conducted at the University of Illinois Chicago. Eighty-nine women ages 19-62 (mean age 30.2 years) with a confirmed vulvodynia diagnosis were randomized 1:1 to either penetrating acupuncture or a validated skin-touch blunt-tip placebo, identical in appearance to the penetrating needle but designed not to break the skin. Both participants and acupuncturists were blinded to group allocation.
All participants received a standardized 13-point protocol (Baihui – GV 20, Qugu – CV 2, Guanyuan – CV 4, and bilateral Henggu – KD 11, Qichong - ST 30, Hegu – LI 4, Sanyinjiao – SP 6, and Taichong – LV 3) over 10 sessions, twice weekly for five weeks, with needles retained for 45 minutes per session. No music, aromatherapy or therapeutic conversation was permitted, specifically to isolate the needling effect from ritual and relational factors.
Responders, defined as those achieving a pain reduction of at least 1.5 points on the Tampon Test (a validated provoked-pain measure), then entered a 12-week follow-up phase during which they recorded their provoked vulvar pain weekly.
Key Findings
At the end of the 10-session treatment period, both groups showed clinically meaningful pain reductions, but no statistically significant difference between penetrating acupuncture and placebo was found for the primary outcome (average vulvar pain intensity) or secondary outcomes (dyspareunia, sexual function). The responder rate was nearly identical: 58% in the acupuncture group and 57% in the placebo group.
The critical finding emerged during the 12-week follow-up. Among responders, placebo participants returned to their baseline pain level at 2.72 times the rate of acupuncture participants. In practical terms, at 28 days post-treatment, half of the placebo responders had already relapsed to baseline pain – compared to just one participant in the penetrating acupuncture group. The acupuncture effect persisted for significantly more responders across the full 12 weeks.
Clinical Relevance for Acupuncture Practitioners
These findings carry important implications for how acupuncturists discuss treatment expectations with vulvodynia patients. While the end-of-treatment results did not statistically separate the groups (likely due to the unusually strong placebo response generated by the convincing skin-touch needle), the durability of benefit clearly favored genuine penetrating acupuncture.
The authors suggest acupuncture’s true efficacy may have been underestimated precisely because the placebo needle was so effective at maintaining participant blinding.
For practitioners, the acupuncture protocol used is replicable: 13 needles inserted perpendicularly with a tapping-in and rotating technique, retained for 45 minutes, delivered twice weekly over five weeks. No adverse events were reported across the entire trial.
Conclusion
This is the first rigorous multi-needle, multi-session, double-blind RCT to demonstrate that the therapeutic effect of penetrating acupuncture for vulvodynia outlasts even a strong placebo response among those who respond to treatment. For a patient population with very few effective options, this is an important and clinically meaningful result. Larger pragmatic trials and future investigation into what distinguishes responders from non-responders are now warranted and well-justified.
Reference
- Schlaeger JM, et al. Long-lasting effect of penetrating acupuncture among responders: double-blind RCT of acupuncture for vulvodynia. J Pain, 2026;38:105584.
